Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Accounts Payables (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Accounts Payables for 10 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 13.13% to $13.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.9 million through Dec 2025, up 13.13% year-over-year, with the annual reading at $13.9 million for FY2025, 13.13% up from the prior year.
  • Accounts Payables for Q4 2025 was $13.9 million at Rhythm Pharmaceuticals, up from $13.6 million in the prior quarter.
  • The five-year high for Accounts Payables was $16.0 million in Q2 2025, with the low at $3.8 million in Q3 2023.
  • Average Accounts Payables over 5 years is $8.4 million, with a median of $6.8 million recorded in 2022.
  • The sharpest move saw Accounts Payables crashed 45.81% in 2024, then soared 251.79% in 2025.
  • Over 5 years, Accounts Payables stood at $5.7 million in 2021, then fell by 16.38% to $4.8 million in 2022, then increased by 1.83% to $4.9 million in 2023, then soared by 152.36% to $12.3 million in 2024, then rose by 13.13% to $13.9 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $13.9 million, $13.6 million, and $16.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.